Valeo Financial Advisors LLC Invests $30,000 in Nuvectra Corp (NASDAQ:NVTR)
Valeo Financial Advisors LLC acquired a new position in shares of Nuvectra Corp (NASDAQ:NVTR) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 22,415 shares of the company’s stock, valued at approximately $30,000. Valeo Financial Advisors LLC owned approximately 0.13% of Nuvectra at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new stake in shares of Nuvectra in the second quarter valued at approximately $1,987,000. Morgan Stanley increased its holdings in shares of Nuvectra by 961.3% in the second quarter. Morgan Stanley now owns 641,932 shares of the company’s stock valued at $2,151,000 after purchasing an additional 581,444 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Nuvectra by 71.5% in the second quarter. Royal Bank of Canada now owns 491,286 shares of the company’s stock valued at $1,646,000 after purchasing an additional 204,777 shares in the last quarter. River & Mercantile Asset Management LLP acquired a new stake in shares of Nuvectra in the second quarter valued at approximately $634,000. Finally, Laurel Wealth Advisors Inc. increased its holdings in shares of Nuvectra by 1,532.3% in the second quarter. Laurel Wealth Advisors Inc. now owns 195,880 shares of the company’s stock valued at $656,000 after purchasing an additional 183,880 shares in the last quarter. 78.10% of the stock is owned by institutional investors.
NVTR traded up $0.30 during trading on Friday, reaching $1.79. 6,499,562 shares of the company’s stock were exchanged, compared to its average volume of 274,066. The company’s fifty day moving average price is $1.57 and its 200-day moving average price is $3.89. The company has a debt-to-equity ratio of 0.58, a quick ratio of 4.42 and a current ratio of 4.86. Nuvectra Corp has a fifty-two week low of $1.24 and a fifty-two week high of $22.13. The firm has a market capitalization of $26.65 million, a PE ratio of -0.56 and a beta of 0.70.
NVTR has been the subject of a number of research reports. Zacks Investment Research lowered shares of Nuvectra from a “buy” rating to a “hold” rating in a report on Wednesday. JMP Securities lowered their target price on shares of Nuvectra to $10.00 and set an “outperform” rating for the company in a report on Thursday, August 1st. They noted that the move was a valuation call. Piper Jaffray Companies lowered their target price on shares of Nuvectra from $18.00 to $4.00 and set an “overweight” rating for the company in a report on Thursday, August 1st. Finally, ValuEngine raised shares of Nuvectra from a “hold” rating to a “buy” rating in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $8.75.
Nuvectra Company Profile
Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.
Want to see what other hedge funds are holding NVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvectra Corp (NASDAQ:NVTR).
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.